SCOLR Pharma, Inc. Issued Fifth Drug Delivery Patent for CDT® Drug Delivery Platform

Business Wire, June 18, 2007

BELLEVUE, Wash. -- SCOLR Pharma, Inc. (AMEX: DDD) today announced that the United States Patent and Trademark Office has issued SCOLR a fifth patent (#7,229,642) entitled "Amino acid modulated extended release dosage form". This new patent is the third for SCOLR Pharma's amino acid-based CDT[R] drug delivery platform.

SCOLR Pharma's amino acid-based technology is one of the patented/proprietary approaches within its CDT drug delivery platform for formulating novel tablets and capsules. The amino acid technology is designed to solve drug formulation challenges by controlling release of the active ingredient independent of the drug's solubility characteristics. SCOLR Pharma believes the additional patent extends its capability to apply its technology to oral drug formulations that could benefit from a controlled release delivery profile with improved manufacturing processes and costs.

Daniel O. Wilds, SCOLR Pharma's President and Chief Executive Officer, said, "This patent is an important addition to our CDT drug delivery patent estate. We believe it strengthens our proprietary position in the use of amino acids in oral drug formulations and expands our opportunities to address the ever increasing number of drugs and nutritional products that present challenging formulation issues."

About SCOLR Pharma:

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.373.0171 or visit http://www.scolr.com/.> This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to successfully develop new formulations and complete research and development, including pre-clinical and clinical studies, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products. And we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.